10-Q: Lilly Soars on Blockbuster Drug Sales, Strong Pipeline

Eli Lilly reports exceptional Q3 and YTD 2025 financial results, driven by surging demand for Mounjaro and Zepbound, alongside significant pipeline advancements.

Summary

• Revenue for the three months ended September 30, 2025, increased by 54% to $17.60 billion, and for the nine months, it rose 46% to $45.89 billion.
• Net income for Q3 2025 dramatically increased to $5.58 billion from $970.3 million in Q3 2024, with year-to-date net income up 127% to $14.00 billion.
• Diluted earnings per share (EPS) for Q3 2025 was $6.21, up from $1.07 in Q3 2024, and year-to-date EPS increased 128% to $15.56.
• Gross margin as a percentage of revenue improved to 82.9% in Q3 2025 (from 81.0% in Q3 2024) and 83.3% year-to-date (from 80.9% in YTD 2024), primarily due to a favorable product mix.
• Mounjaro revenue surged 109% in Q3 2025 to $6.52 billion and 94% year-to-date to $15.56 billion, driven by strong volume growth both in and outside the U.S.
• Zepbound revenue in the U.S. reached $3.57 billion in Q3 2025 and $9.25 billion year-to-date, reflecting increased demand.
• Significant pipeline progress includes new Phase 3 trials for tirzepatide, muvalaplin, orforglipron, and retatrutide, as well as regulatory approvals for Mirikizumab in Japan, Donanemab in the EU, Imlunestrant in the U.S., and Pirtobrutinib in the EU.
• Acquired Verve Therapeutics for approximately $549.4 million cash plus contingent value rights up to $300 million, adding VERVE-102 (gene editing for cardiovascular disease) to the pipeline.
• Issued $6.75 billion in new debt in August 2025 and $6.50 billion in February 2025 for general business purposes and acquisitions, increasing total debt to $42.51 billion.
• Repurchased $2.60 billion of common stock year-to-date under the $15.00 billion program authorized in December 2024, with $12.40 billion remaining.
• Declared a Q4 2025 dividend of $1.50 per share, payable December 10, 2025.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong financial results with significant revenue, net income, and EPS growth driven by blockbuster products. The pipeline is robust with numerous advancements and approvals, and strategic acquisitions are enhancing future prospects. While legal and regulatory challenges exist, the overall operational and financial performance is outstanding.

Positives

• Revenue increased by 54% in Q3 2025 and 46% year-to-date, demonstrating robust top-line growth.
• Net income and diluted EPS saw substantial increases of 127% and 128% year-to-date, respectively, indicating strong profitability.
• Gross margin as a percentage of revenue improved by 1.9 percentage points in Q3 2025 and 2.4 percentage points year-to-date, driven by a favorable product mix and improved cost of production.
• Mounjaro and Zepbound continue to be significant growth drivers, with Mounjaro revenue up 109% in Q3 2025 and Zepbound showing substantial demand-driven growth.
• Verzenio revenue increased 7% in Q3 2025 and 10% year-to-date, contributing to oncology segment growth.
• Jardiance revenue increased, including a $370.0 million one-time benefit from a collaboration amendment and a $200.0 million sales-based milestone.
• The pipeline saw multiple positive developments, including new Phase 3 trial initiations for several key compounds and regulatory approvals for Mirikizumab, Donanemab, Imlunestrant, and Pirtobrutinib.
• Cash and cash equivalents significantly increased to $9.79 billion as of September 30, 2025, from $3.27 billion at December 31, 2024, enhancing liquidity.
• The acquisition of Verve Therapeutics adds a promising gene editing medicine (VERVE-102) for cardiovascular disease with Fast Track designation.
• The enactment of the One Big Beautiful Bill Act (OBBBA) in July 2025 made permanent the immediate deductibility of U.S. research and development expenses and reinstated 100% bonus depreciation for capital assets, which could be favorable long-term.

Negatives

• Increased marketing, selling, and administrative expenses (up 31% in Q3 2025 and 29% year-to-date) and research and development expenses (up 27% in Q3 2025 and 20% year-to-date) reflect higher investment but also increased cost base.
• Lower realized prices for Mounjaro and Zepbound in the U.S. partially offset volume increases.
• The effective tax rates for Q3 and YTD 2025 were unfavorably impacted by incremental tax expense recognized due to the OBBBA and non-deductible acquired IPR&D charges.
• Asset impairment, restructuring, and other special charges of $364.9 million in Q3 2025 and $399.9 million year-to-date, primarily related to a litigation charge and acquisition/integration costs.

Risks

• Significant costs and uncertainties in pharmaceutical R&D, including regulatory approval timing and process.
• Impact and uncertain outcome of acquisitions and business development transactions and related costs.
• Intense competition affecting products, pipeline, or industry.
• Continued pricing pressures and actions by governmental and private actors affecting pricing, reimbursement, and patient access to pharmaceuticals.
• Safety or efficacy concerns associated with products or competitive products.
• Dependence on relatively few products or product classes for a significant percentage of total revenue and a consolidated supply chain.
• Expiration of intellectual property protection and competition from generic and biosimilar products.
• Ability to protect and enforce patents and other intellectual property, and changes in patent law or regulations.
• Information technology system inadequacies, security breaches, or operating failures, including unauthorized access or compromise of confidential information.
• Issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including unpredictability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions.
• Reliance on third-party relationships and outsourcing arrangements.
• The use of artificial intelligence or other emerging technologies may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks.
• Impact of global macroeconomic conditions, including uneven economic growth, trade disputes, international tension, and conflicts.
• Fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation.
• Litigation, investigations, or other similar proceedings involving past, current, or future products or activities, including patent, environmental, labor, 340B program, insulin pricing, and average manufacturer price (AMP) litigation.
• Changes in tax law and regulation, tax rates, or events that differ from assumptions related to tax positions.
• Regulatory changes, developments, and uncertainty, including regulatory oversight and actions regarding operations and products.
• Risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products, particularly for incretin medicines.
• Actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.
• Asset impairments and restructuring charges.
• Regulatory focus on business combinations in the industry could delay, jeopardize, or increase costs of business development activities.

Future Outlook

Eli Lilly anticipates continued strong demand for its incretin medicines, with ongoing production increases and additional capacity expected over the next several years. The company is evaluating the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on future disclosures. Management expects to use net cash proceeds from recent debt offerings for general business purposes, including repayment of commercial paper. The company also expects meaningfully higher capital expenditures over the next several years to expand manufacturing capacity. The Inflation Reduction Act (IRA) and other global pricing pressures are expected to continue to influence business strategies and could significantly impact results, with Jardiance already selected for government-set prices in 2026 and other significant products potentially following. The company continues to monitor and address the proliferation of counterfeit and unapproved incretin medicines.

Management Comments

• Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines.
• We view our business development activity as a way to enhance or refine our pipeline and strengthen our business.
• We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements.
• We are making investments in global facilities to manufacture existing and future products, which will result in meaningfully higher capital expenditures over the next several years.
• Demand for our incretin medicines exceeded production at various times during 2024, and while tirzepatide supply currently exceeds demand in the U.S., demand in launched markets remains dynamic, potentially leading to periodic unavailability of certain presentations and dose levels.
• Lilly will continue to consider all options, including filing lawsuits where appropriate, to address unlawful practices and the patient safety risks of unapproved, untested, and manipulated drugs (referring to counterfeit incretins).

Industry Context

Eli Lilly's exceptional growth, particularly in cardiometabolic health with Mounjaro and Zepbound, positions it as a leader in the rapidly expanding GLP-1 agonist market for diabetes and obesity. This growth occurs amidst intense global scrutiny on pharmaceutical pricing, with governments and private payers implementing cost containment measures like mandated discounts and reference pricing. The U.S. Inflation Reduction Act (IRA) and executive orders on drug pricing are significant industry headwinds, directly impacting Lilly's products like Jardiance. The company's aggressive R&D investment and strategic acquisitions reflect a broader industry trend of seeking innovation to maintain competitive advantage and address unmet medical needs, while also navigating complex regulatory and supply chain challenges, including the rise of counterfeit products.

Comparison to Industry Standards

• Lilly's Q3 2025 revenue growth of 54% and YTD growth of 46% significantly outpaces the average growth rates of major pharmaceutical companies, which typically range in the single to low double digits, demonstrating exceptional market penetration and demand for its key products like Mounjaro and Zepbound.
• The gross margin improvement to 82.9% in Q3 2025 and 83.3% YTD is at the higher end of the pharmaceutical industry, indicating strong pricing power and efficient production, especially compared to companies facing more intense generic competition or less differentiated portfolios.
• Lilly's substantial investment in R&D, with expenses up 27% in Q3 2025 and 20% YTD, reflects a commitment to innovation comparable to other top-tier biopharmaceutical companies like Pfizer or Merck, which also maintain high R&D spending to fuel their pipelines.
• The rapid advancement of multiple compounds into Phase 3 trials (e.g., tirzepatide, orforglipron, muvalaplin, retatrutide) and numerous regulatory approvals (e.g., Donanemab, Imlunestrant, Pirtobrutinib) indicates a highly productive pipeline, potentially outperforming peers in terms of clinical development milestones in the current period.
• The acquisition of Verve Therapeutics for gene editing technology aligns with a broader industry trend of investing in advanced therapeutic modalities, similar to moves by companies like Vertex Pharmaceuticals in gene therapy or CRISPR Therapeutics in gene editing, positioning Lilly at the forefront of innovative medicine.
• The challenges with incretin medicine supply and the proliferation of counterfeit products highlight industry-wide issues in managing high-demand, complex biologics, a concern shared by competitors like Novo Nordisk with its GLP-1 products Ozempic and Wegovy.

Legal Proceedings

• Emgality Patent Litigation: Teva's appeal to the U.S. Court of Appeals for the Federal Circuit is pending after a trial court overruled a jury verdict in Teva's favor and found asserted claims invalid.
• Brazil Litigation Cosmopolis Facility Labor Attorney Litigation: Appeals to the superior labor court (TST) are pending regarding a trial court ruling against Lilly Brasil, which included a liquidated award of approximately $290 million (adjusted for inflation). A freeze on Lilly Brasil's immovable property (approximately $30 million) is also under appeal.
• 340B Litigation and Investigations: Lilly's lawsuit against HHS challenging the 340B program is pending appeal at the U.S. Court of Appeals for the Seventh Circuit. The U.S. Court of Appeals for the Second Circuit reversed the dismissal of a class action lawsuit against Lilly and others, with Lilly's petition for rehearing en banc pending. Various other ADR petitions and state investigations are ongoing.
• Insulin Pricing Litigation: Multidistrict litigation (MDL) is ongoing, with various claims including consumer protection, antitrust, and fraud. The Michigan Supreme Court granted leave to appeal a state investigation. Lilly reached non-monetary settlements with the Minnesota and New York attorneys general.
• Average Manufacturer Price (AMP) Litigation: The U.S. Court of Appeals for the Seventh Circuit affirmed a jury verdict against Lilly, and Lilly has filed a petition for rehearing en banc. A charge related to this matter was recognized.
• Actos Litigation: The U.S. Court of Appeals for the Ninth Circuit denied Lilly's appeal of a class certification order and a petition for rehearing en banc in a third-party payer class action.
• Mounjaro, Trulicity, and Zepbound Product Liability Litigation: Multiple lawsuits alleging injuries from incretin medicines are coordinated in a federal MDL in Pennsylvania, with two class action petitions also filed in Israel.
• Branchburg Manufacturing Facility: Lilly is cooperating with a U.S. Department of Justice subpoena requesting documents related to its manufacturing site.
• Health Choice Alliance: A relator dismissed an initial lawsuit and filed a second, broader lawsuit in Texas state court, asserting claims under the TMFPA related to patient support programs for fifteen products, with the State of Texas now a party.
• Research Corporation Technologies, Inc. (RCT) Litigation: Lilly reached a confidential agreement with RCT regarding a breach of contract lawsuit related to manufacturing processes, and Lilly's appeal to the U.S. Court of Appeals for the Ninth Circuit is pending.

Related Party Transactions

• Collaboration with Boehringer Ingelheim: Jointly develop and commercialize a portfolio of compounds, including the Jardiance product family. Lilly and Boehringer Ingelheim generally share equally in certain development and commercialization costs. Lilly receives a royalty on net sales of Jardiance and is eligible for potential sales-based milestones up to $410.0 million in 2026. An amendment in Q1 2025 resulted in a $370.0 million one-time benefit for Lilly.
• License agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (Roche): Lilly has worldwide development and commercialization rights to Ebglyss (lebrikizumab). Roche receives tiered royalty payments on worldwide net sales and is eligible for up to $975.0 million in potential sales-based milestones.
• License agreement with Almirall, S.A.: Almirall licensed rights to develop and commercialize Ebglyss in Europe for dermatology indications. Lilly receives tiered royalty payments on net sales in Europe and is eligible for up to $1.25 billion in sales-based milestones.
• License agreement with Chugai Pharmaceutical Co., Ltd: Lilly has worldwide development and commercialization rights to orforglipron. Chugai has the right to receive tiered royalty payments on future worldwide net sales and is eligible for up to $140.0 million in regulatory milestones and up to $250.0 million in sales-based milestones.

Stakeholder Impact

• Shareholders: Benefited from significant increases in revenue, net income, and EPS, as well as a declared Q4 2025 dividend of $1.50 per share and ongoing share repurchase program.
• Patients: Access to new medicines through pipeline advancements and regulatory approvals (e.g., Mirikizumab, Donanemab, Imlunestrant, Pirtobrutinib). However, potential periodic unavailability of certain incretin medicine presentations and the risk of counterfeit products pose challenges.
• Employees: The acquisition of Verve Therapeutics includes its assembled workforce. Increased R&D and marketing expenses suggest continued investment in personnel.
• Customers (Wholesale distributors, pharmacies, healthcare providers): Affected by pricing pressures, 340B program litigation, and potential supply chain disruptions for high-demand products.
• Creditors: New debt issuances in 2025 increased total debt to $42.51 billion, but the company maintains substantial cash and credit facilities, indicating strong liquidity management.

Next Steps

• Continue to monitor the appeal of the Emgality patent litigation at the U.S. Court of Appeals for the Federal Circuit.
• Monitor the ongoing appeals to the superior labor court (TST) in the Brazil Cosmopolis facility labor attorney litigation.
• Await resolution of the U.S. Court of Appeals for the Seventh Circuit appeal and the pending rehearing en banc petition in the 340B litigation.
• Monitor the Michigan Supreme Court's appeal process regarding the state's insulin pricing investigation.
• Await resolution of Lilly's petition for rehearing en banc in the AMP litigation.
• Continue to cooperate with the U.S. Department of Justice subpoena regarding the Branchburg manufacturing facility.
• Address the second lawsuit filed by the relator in the Health Choice Alliance matter, which now includes the State of Texas and claims related to fifteen products.
• Monitor Lilly's appeal to the U.S. Court of Appeals for the Ninth Circuit regarding the RCT litigation.
• Continue to expand manufacturing capacity to meet existing and expected demand for medicines, particularly incretins.
• Actively address the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins, including potential lawsuits.
• Evaluate the potential impact of adopting new accounting standards ASU 2023-09 (effective for fiscal years beginning after December 15, 2024) and ASU 2024-03 (effective for annual reporting periods beginning after December 15, 2026).
• Continue to manage foreign currency exchange risk through hedging and other risk management techniques.
• Monitor the implementation of the Inflation Reduction Act (IRA) and other global drug pricing initiatives, especially as they relate to additional products being selected for government-set prices.

Key Dates

Recommendation

Eli Lilly's Q3 2025 results demonstrate exceptional financial performance, driven by the continued blockbuster success of Mounjaro and Zepbound, which are dominating the cardiometabolic health market. The company's robust pipeline, with multiple compounds advancing to Phase 3 and several recent regulatory approvals, signals sustained future growth. While increased operating expenses and ongoing legal/regulatory challenges, particularly around drug pricing, are noted, the sheer scale of revenue and earnings growth, coupled with strategic acquisitions and a strong balance sheet, positions Lilly for continued market leadership. The current valuation, while high, is justified by its innovation engine and market-leading products. Investors should consider a 'strong buy' given the company's impressive growth trajectory and future prospects.

Keywords

Pharmaceuticals, Biotechnology, Drug Development, Mounjaro, Zepbound, Verzenio, Tirzepatide, Orforglipron, Obesity, Diabetes, Oncology, Cardiometabolic Health, Immunology, Neuroscience, SEC Filing, 10-Q, Financial Results, Pipeline, Acquisitions, R&D, GLP-1, Drug Pricing, Patent Litigation